Search Product
Structure Search
Search
Online Support
-
Customer service
Advantage Products
Location: Industrial Info
Australian researchers develop new therapies to reduce the risk of kidney failure in diabetic patients
2019-04-18
来源：转载自第三方
In China, about half of adult diabetic patients do not achieve the recommended level of glycemic control. For these patients, the potential for complications is increased, such as heart disease, stroke, kidney failure and diabetic retinopathy. Among them, cardiovascular disease has become the leading cause of death in diabetic patients, and diabetic nephropathy is the leading cause of end-stage renal disease.
Australian researchers have developed a new treatment that can reduce the risk of kidney failure in diabetics by a third. It has also been reported that this treatment can reduce the incidence of heart failure in diabetics by more than 30% and the risk of other major cardiovascular diseases by about 20%. This is expected to benefit hundreds of millions of people with diabetes worldwide.
The researchers recruited 4,401 diabetic patients from more than 30 countries and regions to participate in clinical trials. Half of the volunteers were given the drug calpagliflozin based on the current treatment regimen, while the other half of the control group received a placebo.
The drug, Canagliflozin, was originally developed to reduce blood sugar levels in diabetic patients. Compared with other hypoglycemic agents, Canagliflozin has a significant role in reducing cardiovascular disease and protecting the kidneys in diabetic patients. But the latest study shows that after taking Canagliflozin, diabetics have a 30% lower risk of developing kidney failure or dying from kidney failure. In addition, the risk of cardiovascular disease such as heart failure is also significantly reduced. Studies have shown that taking this drug does not increase the risk of major side effects.
Diabetes is a chronic condition with major complications including kidney failure, heart disease and stroke. The study's lead author, Professor Vlado Perkovic of the George Institute for Global Health in Australia, said in a press release that the study was "a major medical breakthrough" because "diabetes and kidney patients face kidney failure" The risk of heart disease, stroke and death is high, and this effective treatment can only reduce this risk by taking it once a day."
Edited by Suzhou Yacoo Science Co., Ltd.
如果涉及转载授权，请联系我们。
